ATHENRY, Ireland--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), a global leader in continuous glucose monitoring, today officially opened its state-of-the-art manufacturing facility in Athenry, County Galway, marking a major milestone in the company's investment in Ireland and its manufacturing presence in Europe, the Middle East and Africa. The official opening ceremony, attended by Minister for Public Expenditure, Infrastructure, Public Service Reform and Digitalisation, Jack Chambers, TD; Mi.
DexCom NASDAQ: DXCM expects a record number of new patients in 2026 and is preparing for a potential expansion of Medicare coverage for continuous glucose monitoring, executives said during a discussion hosted by Jefferies.
DexCom, Inc. (DXCM) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Aberdeen Group plc cut its holdings in DexCom, Inc. (NASDAQ: DXCM) by 14.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,252 shares of the medical device company's stock after selling 67,550 shares during the period. Aberdeen Group plc owned
Commonwealth Equity Services LLC raised its position in DexCom, Inc. (NASDAQ: DXCM) by 18.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 70,241 shares of the medical device company's stock after purchasing an additional 10,738 shares during the period. Commonwealth Equity Services LLC's holdings in
DexCom's G7 15 Day adoption, international expansion and margin gains support its growth prospects, though competition and rising investments pose challenges.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026.The live presentation is scheduled to begin at approximately 2:00 PM GMT (9:00 AM EST) and will be concurrently webcast.Links to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com and will be archived there for future reference.About DexCom, Inc.
DXCM's upcoming Canadian launch of the G7 15 Day CGM, offering longer sensor wear and improved convenience, could boost international growth and patient access.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today launched A Letter to Diabetes in honor of National Diabetes Awareness Month and World Diabetes Day, creating a platform for people around the world to put into words everything they've wanted to say about their diabetes journey, from the heartfelt and humorous to the hopeful and unexpected.Throughout November, anyone touched by diabetes is invited to share their own letter to diabetes, includi.
DXCM's recurring sensor model synergizes nicely with wider diabetes access thanks to Medicare. In fact, broader Medicare coverage could expand their overall addressable market, as long as DXCM is able to execute on that expanded opportunity. Also, DXCM now offers longer-wear sensors, and they intend to increase their manufacturing scale. So, those factors combined could improve margins as well.